Enveric Biosciences Inc. (ENVB)
0.36
-0.01 (-1.91%)
At close: Jan 15, 2025, 10:17 AM
undefined% (undefined)
| Bid | 0.36 |
| Market Cap | 3.62M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.42 |
| PE Ratio (ttm) | -0.15 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.36 |
| Volume | 81,058 |
| Avg. Volume (20D) | 393,419 |
| Open | 0.36 |
| Previous Close | 0.37 |
| Day's Range | 0.35 - 0.37 |
| 52-Week Range | 0.30 - 2.92 |
| Beta | undefined |
About ENVB
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosc...
Industry Biotechnology
Sector Healthcare
IPO Date May 4, 2015
Employees 7
Stock Exchange NASDAQ
Ticker Symbol ENVB
Website https://www.enveric.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ENVB stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 2708.99% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
10 months ago ·
Source
+8.18%
Enveric Biosciences shares are trading higher afte...
Unlock content with
Pro Subscription
10 months ago ·
Source
+74.49%
Enveric Biosciences shares are trading higher after the company announced it signed three non-binding term sheets to pursue the out-licensing of three classes of compounds.
